- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Shorter treatment for hepatitis C virus may be possible with protease inhibitor
Analysis of the hepatitis C virus kinetics during treatment with protease inhibitor telaprevir shows a rapid decline, according to a new study.
Key Points
Analysis of the hepatitis C virus (HCV) kinetics during treatment with protease inhibitor telaprevir shows a rapid viral decline, which could allow for shorter treatment, according to a study published online in Hepatology.
Chronic HCV infection has a worldwide prevalence of about 3%. Achieving a long-term sustained virologic response (SVR), defined as undetectable HCV RNA in serum 24 weeks after the end of treatment, is the most effective way to prevent disease progression. Currently, treatment outcome with pegylated interferon and ribavirin is correlated with HCV genotype and SVR is only achieved in half of HCV genotype 1 patients, the most prevalent genotype in western countries.
Researchers Jeremie Guedj, PhD, and Alan S. Perelson, PhD, from the Los Alamos National Laboratory in New Mexico, examined HCV viral decline during treatment with telaprevir.
The researchers found that the second-phase viral decline was associated with the effectiveness of treatment, and was about 4 times more rapid with telaprevir than interferon-based therapies. Also the viral kinetics were consistent across patients and dosing-group regimen and did not reveal variations as large between patients as when treated with the standard of care.
"We determined that, if resistance could be avoided and assuming full compliance to treatment, 7 to 10 weeks of treatment would be sufficient to clear HCV with telaprevir in 95% of patients," Guedj said. "This result may drive future clinical trials. However to attain SVR in 95% of treatment-compliant patients with a 10-week course of therapy will require treatments with 3 or more direct-acting antivirals including ribavirin. Clearly, at present there are no approved regimes that meet our criteria of high potency and a high enough barrier to resistance."
SOURCE
Guedj J, Perelson AS. Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness: Implications for treatment. Hepatology. 2011;Mar 7 doi:10.1002/hep.24272 [Epub ahead of print].
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
